22/10/2008
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’) wishes to draw the attention of interested parties to concerns that have recently been expressed to the Company, regarding an approach to certain shareholders to sell the shares that they hold in ReGen at heavily inflated prices.
It is the Company’s understanding that some shareholders may be contacted by seemingly authorised institutions, who will offer to purchase ReGen shares at prices that are significantly and unrealistically higher than the prevailing market values. For their own protection, shareholders should always check that any firm they speak to with regard to their shares are authorised and regulated by the Financial Services Authority (the “FSA”). The register of regulated firms and their agents is available on the FSA website www.fsa.gov.uk
Whist the Company’s Board of Directors cannot comment on any specific details that have been disclosed to them, as a courtesy to shareholders, they have decided to bring the matter to the attention of a wider audience and would recommend that any shareholder approached in the manner described above should also consult an independent financial advisor prior to taking any action to dispose of their shares.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel: 020 7448 9820
Adrian Duffield/Jon Davies
College Hill Associates
Tel: 020 7457 2020